CN Patent

CN105555313A — 在c-反应蛋白水平较高的实体肿瘤患者中的存活益处

Assigned to Incyte Corp · Expires 2016-05-04 · 10y expired

What this patent protects

本申请涉及通过向实体肿瘤患者施用JAK抑制剂或IL-6信号传导抑制剂来增加所述患者的存活时间或无进展存活时间的方法，其中所述患者的C-反应蛋白(CRP)的血清浓度较高，以及预测这些患者从这种疗法获得的存活益处的方法。

USPTO Abstract

本申请涉及通过向实体肿瘤患者施用JAK抑制剂或IL-6信号传导抑制剂来增加所述患者的存活时间或无进展存活时间的方法，其中所述患者的C-反应蛋白(CRP)的血清浓度较高，以及预测这些患者从这种疗法获得的存活益处的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN105555313A
Jurisdiction
CN
Classification
—
Expires
2016-05-04
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.